MYNZ MAINZ BIOMED BV

Mainz Biomed Recognizes Colorectal Cancer Awareness Month Throughout “Blue” March 2023

Mainz Biomed Recognizes Colorectal Cancer Awareness Month Throughout “Blue” March 2023

Mainz Biomed to host several events for patients and healthcare professionals in Germany to increase awareness about the importance of early detection of colorectal cancer. 

BERKELEY, Calif. and MAINZ, Germany, March 01, 2023 (GLOBE NEWSWIRE) -- (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, joins advocacy organizations around the world in recognizing Colorectal Cancer Awareness Month in March. Colorectal cancer is the third most common cancer globally, with more than 1.9 million new cases in 2020. This year, Mainz Biomed will be hosting several educational and training events throughout Germany to raise awareness of the importance of early detection.

“We have developed these events to support the colorectal cancer community, as this disease is the third most common cancer globally and the fourth leading cause of cancer death in the US,” said Guido Baechler, Chief Executive Officer of Mainz Biomed. “Our goal is to reduce these statistics and save lives by raising awareness about the simplicity and efficacy of using at-home CRC detection kits, like ColoAlert. Our non-invasive DNA stool test allows people to screen themselves in the comfort of their own home and then receive a follow-up notification from their physician to discuss results and next steps.”

Upcoming Colorectal Cancer Awareness Month Events

Professionals

Training Sessions for gastroenterologists, healthcare providers

Gastro-Update Conference;

#1 Friday and Saturday, March 10-11, 2023 (Time TBD)

Rheingoldhalle; Mainz

#2 Friday and Saturday, March 24-25, 2023 (Time TBD)

Berlin Congress Center; Berlin/

Public

Educational Event for patients, families, caregivers, advocates

Saturday, March 11, 2023 (09:00-16:00)

(Outdoor event venue TBD); Mainz Altstadt

Mainz Biomed invites others to further amplify awareness of CRC by using the #BlueForCRC and #CRCAwareness hashtags on social media and “going blue” on Friday, March 3 by dressing in blue!

For media inquiries, please contact In Europe:

MC Services AG

Anne Hennecke/Caroline Bergmann

20





In the US:

Spectrum Science

Melissa Laverty/Valerie Enes



For investor inquiries, please contact 



EN
01/03/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on MAINZ BIOMED BV

 PRESS RELEASE

Mainz Biomed Announces Pricing of $4.0 Million Follow-On Offering of O...

Mainz Biomed Announces Pricing of $4.0 Million Follow-On Offering of Ordinary Shares and Warrants BERKELEY, Calif. and MAINZ, Germany, May 19, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, today announced the pricing of a follow-on offering of 2,000,000 units, with each unit consisting of one ordinary share (or pre-funded warrant in lieu thereof), one Series A warrant to purchase one ordinary share, and one Series B warrant to purchase one ordinary share for...

 PRESS RELEASE

Mainz Biomed Announces Interim Read Out For Its eAArly DETECT 2 Clinic...

Mainz Biomed Announces Interim Read Out For Its eAArly DETECT 2 Clinical Study Company intends to provide an interim read out by the end of summer 2025 Top-line results anticipated in Q4 2025; study on track to support U.S. pivotal trial initiation in 2026 BERKELEY, Calif. and MAINZ, Germany, May 16, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today that it intends to provide an interim read out of its eAArly DETECT 2 feasibility study by the e...

 PRESS RELEASE

Mainz Biomed Enters into Technology Partnership with EDX Medical Group

Mainz Biomed Enters into Technology Partnership with EDX Medical Group BERKELEY, Calif. and MAINZ, Germany, April 29, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, has entered into a technology partnership with UK-based EDX Medical Group plc (AQSE: EDX), which develops innovative digital diagnostic products and services supporting personalized treatments for cancer, cardiovascular and infectious diseases. Under the agreement, EDX Medical will access Mainz B...

 PRESS RELEASE

Mainz Biomed Provides First Quarter 2025 Corporate Update and Path to ...

Mainz Biomed Provides First Quarter 2025 Corporate Update and Path to FDA Premarket Approval BERKELEY, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ: MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, today reviewed its major accomplishments of the first quarter of 2025, and provided an outlook on its path to FDA premarket approval.   During the first quarter of 2025: Path to FDA premarket approval: The Company enrolled the first patient into its feasibility study eAArly DETEC...

 PRESS RELEASE

EQS-News: Mainz Biomed Reports 2024 Financial Results and Provides Cor...

Issuer: Mainz BioMed N.V. / Key word(s): Annual Results Mainz Biomed Reports 2024 Financial Results and Provides Corporate Update 01.04.2025 / 14:01 CET/CEST The issuer is solely responsible for the content of this announcement. Mainz Biomed Reports 2024 Financial Results and Provides Corporate Update Lab network revenue increased by 33% year over year, reflecting strong demand for ColoAlert® in Europe Operating loss decreased by 30% and net loss by 18%, driven by targeted cost reductions and a sharper strategic focus Strategic partnerships with industry leaders mark k...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch